Skip to content

The role of mindfulness training in reducing rumination in recurrent depression

The role of Mindfulness-Based Cognitive Therapy in reducing rumination in recurrent depression: the effect on attention and emotion regulation functions

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN18001392
Enrollment
80
Registered
2018-11-22
Start date
2016-05-01
Completion date
Unknown
Last updated
2024-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent major depressive disorder Mental and Behavioural Disorders Recurrent depressive disorder

Interventions

Mindfulness-based Cognitive Therapy with waiting list control. Standard randomization, stratified for gender. Blinded assessment pre- and post intervention. Mindfulness Based Cognitive Therapy (MBCT)

Sponsors

University of Bergen
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Clinical group: 1. Age: 18 - 70 years old 2. Both genders 3. At least three previous depressive episodes, and to currently fulfill the diagnostic criteria for recurrent depression, and in full/partial remission from depression 4. Patients may continue on antidepressant while participating in the study. It is, however, important that they do not discontinue or change dosage of medication while receiving the interventions of MBCT 5. No current neurological, cardiac or hormonal diseases 6. Borderline Personality Disorder (as assessed by SCID-II) Healthy control group: 1. Age: 18-70 years old 2. No current or prior psychiatric illness (as indicated by M.I.N.I.) 3. No current neurological, cardiac or hormonal diseases

Exclusion criteria

Exclusion criteria: 1. Acute suicidal danger, a lifetime history of psychosis/schizophrenia, bipolar disorder, substance use disorders 2. Ongoing or mindfulness based treatment past 2 years 3. Ongoing psychotherapy 4. Pregnant/lactating

Design outcomes

Primary

MeasureTime frame
Attention regulation processes will be the primary outcome measures. Intra-individual variability in reaction times and default mode activity during cognitive control processing will be used as measures of attentional lapses. Attentional lapses and cognitive control will be measured with performance based test measures. In a subsample brain activation will be measured using functional Magnetic Resonance Imaging (fMRI). Further, self-reported questionnaire data will be applied to measure the degree of ruminative thought (RRQ), and the correlation between intra-individual variance of reaction times, Default Mode activity and ruminative thought processes. Heart Rate Variability (HRV) will be used as a psychophysiological measure of cognitive control. All the outcome measures are administered at baseline and at 8 weeks following post treatment. The primary outcome of level of rumination (RRQ) is also measured after 6 months, 1, and 2 years.

Secondary

MeasureTime frame
1. Facets of mindfulness, emotion regulation, self-compassion, attachment, childhood trauma, personality traits, depression and anxiety symptoms, and early attention processing 2. Emotion regulation and self-compassion measured with self-report, qualitative interviews, emotion recognition task, and with HRV 3. Early attachment with significant others, traumatic childhood experiences, and personality traits measured with self-reports, and outcome of MBCT measured with change scores in depressive symptoms and in mindfulness facets from pre- to post-intervention 4. Early attention processing measured with cue conditions during cognitive control processing (the Attention Network Test Revised Version) 5. Basic abilities such as intelligence (assessed with Wechler Abbreviated Scale of Intelligence) and processing speed (assessed with trail making test) All the outcome measures are administered at baseline and at 8 weeks following post treatment. After 6 months, 1, and 2 years, selected outcome measures are administered. This includes the primary outcome of level of rumination (RRQ) together with relapse of depressive episodes. Further, the participants also fill out the following self-report questionnaires: 1. Depressive symptoms, measured with Beck Depression Inventory (BDI) 2. Anxiety, measured with Beck Anxiety Inventory (BAI) 3. Difficulties with emotion regulation, measured with Difficulties in Emotion Regulation Scale (DERS) 4. Self-compassion, measured with Self-Compassion Scale (SCS) 5. Mindfulness, measured with the Five Facet Mindfulness Questionnaire (FFMQ)

Countries

Norway

Contacts

Public ContactElisabeth Schanche

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 18, 2026